Applied Catalysis A: General (2019)
Update date:2022-08-11
Topics:
Ojelade, Opeyemi A.
Zaman, Sharif F.
Daous, Muhammad A.
Al-Zahrani, Abdulrahim A.
Malik
Driss, Hafedh
Shterk, Genrikh
Gascon
We report the compositional optimization of Pd:Zn/CeO2 catalysts prepared via sol-gel chelatization for the hydrogenation of CO2 under mild reaction conditions. The formation of a PdZn alloy, which is the main active phase for this reaction, was maximized for the catalyst with a Pd to Zn ratio close to 1. For this catalyst, a maximum conversion of 14%, close to thermodynamic equilibrium, and high selectivity to methanol (95%) were achieved at 220 °C, 20 bar, 2400 h?1 GHSV and H2:CO2 stoichiometric ratio of 3:1. The formation of PdZn alloys was achieved by reducing the catalyst precursor at 550 °C under hydrogen flow and confirmed by XRD. XPS study confirmed the presence of Pd°, being maximum for the optimized catalyst composition. At lower temperature, i.e. 180 °C, 1.0PdZn catalyst showed 100% selectivity to methanol with 8% CO2 conversion. RWGS reaction is responsible for the production of CO and its selectivity increases with temperature. In situ DRIFTS suggests that CO2 is activated as adsorbed CO3- species over CeO2. Surface micro-kinetics demonstrates that methanol can be formed either via formaldehyde or formic acid surface intermediates.
View MoreContact:86-532-68629711 13780605697
Address:NO 220 YANAN 3 ROAD,(POST ADMINISTRATION BUILDING),QINGDAO,CHINA
HANGZHOU TOYOND BIOTECH CO., LTD
Contact:+86-571-86965177
Address:No. 189, Fengqi East Road, Hangzhou, China
Contact:+86-535-8888888
Address:No.161 Haishi Rd.
Beijing Green Guardee Technology CO,.LTD
Contact:+86-10-69706062
Address:F2 BLdj,5 No.37 Chaoqian Road
Nanjing Raise Pharmatech Co., Ltd
website:http://www.raisechem.com
Contact:+86-25-58649566
Address:B381,No.606,Ningliu Road,Jiangbei New Area,Nanjing,Jiangsu Province,China
Doi:10.1016/S0040-4039(00)87720-5
(1982)Doi:10.1016/j.tet.2010.04.099
(2010)Doi:10.1016/S0020-1693(00)94060-X
(1976)Doi:10.1080/0049825021000017894
(2003)Doi:10.3390/pharmaceutics13050642
(2021)Doi:10.1007/s10600-013-0642-9
(2013)